Product Images Tamsulosin Hydrochloride

This is a prescription medication for Tamsulosin HCI 0.4 mg capsules. The package contains 30 capsules and the source NDC is 57237-0014-05. The medication should be stored between 20-25°C (68-77°F) with excursions permitted to 15-30°C (53-86°F) and it is manufactured by Rising Pharma, Inc. in Allendale, NJ. The medication should be kept out of reach of children and RemedyRepack Inc. in Indiana, PA has repackaged it. There are no directions for use provided in the text.*

This is medication information for Tamsulosin HCI, a 0.4mg capsule, packaged by RemedyRepack Inc., with manufacturer information for Rising Pharma in Allendale, NJ. The prescription is kept away from children, and directions for use can be found in the package insert. Storage temperature recommendations are also included.*

This is a prescription drug called Tamsulosin HCl, provided as a 0.4 mg capsule manufactured by Rising Pharma, Inc. The package insert contains the directions for use, and it should be kept away from children. The drug should be stored at 20-25°C (83-77°F) with some excursions permitted. It has been repackaged by RemedyRepack Inc. at Indiana, PA. Further information is not available.*

This appears to be a figure showing the mean change from baseline in total AUA symptom score in Study 1. The figure shows two treatment groups, one receiving a medication of 0.08mg and the other receiving a placebo. The X-axis indicates the duration of treatment in weeks, and the Y-axis indicates the mean change from baseline in total AUA symptom score. The figure displays data points at different time intervals. The study included at least 758 participants with varying sample sizes in subsequent time intervals.*

This text is a description of a figure showing the mean change from baseline in AUA symptom score for a study with different treatments. It includes a graph with three treatments, 0.2mg, 0.4mg, and Placebo, and a line chart representing the change from baseline in AUA symptom score. The chart includes data points at weeks 0, 1, 2, 5, 9, 13 and LOCF, and sample sizes for each treatment at each time point.*

The figure 3A displays the mean increase in the peak urine flow rate measured in L/sec in study 1. The treatment groups were 0.08mg, 2x 0.4mg, and Placebo. The mean change in mL/sec was recorded and plotted against the duration of the treatment measured in weeks. The graph displays the corresponding numerical data for each treatment group with their respective sample sizes.*

This appears to be a graph or chart titled "Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2" showing the increase in urine flow rate as measured in milliliters per second for a treatment over a period of weeks. Without more context about the treatment, it is difficult to provide further information.*